Core Viewpoint - Pfizer's upcoming earnings report is anticipated to show a significant decline in earnings and revenue compared to the previous year, raising investor interest [2][3]. Group 1: Stock Performance - Pfizer's stock increased by 1.16% to $24.51, outperforming the S&P 500's daily gain of 0.53% [1]. - Over the past month, Pfizer's stock has risen by 0.33%, which is below the Medical sector's gain of 2.87% and the S&P 500's gain of 0.71% [1]. Group 2: Earnings Estimates - Analysts expect Pfizer to report earnings of $0.68 per share on November 4, 2025, reflecting a year-over-year decline of 35.85% [2]. - The Zacks Consensus Estimate for Pfizer's revenue is projected at $16.81 billion, down 5.06% from the previous year [2]. Group 3: Full Year Projections - For the full year, the Zacks Consensus Estimates project earnings of $3.07 per share and revenue of $63.4 billion, indicating changes of -1.29% and -0.36% respectively from the prior year [3]. Group 4: Analyst Revisions and Rankings - Recent changes to analyst estimates for Pfizer are crucial as they reflect short-term business trends, with positive revisions indicating analyst optimism [3][4]. - Pfizer currently holds a Zacks Rank of 3 (Hold), with a 1.87% decline in the Zacks Consensus EPS estimate over the past month [5]. Group 5: Valuation Metrics - Pfizer's Forward P/E ratio is 7.88, significantly lower than the industry average of 14.5, suggesting it is trading at a discount [6]. - The PEG ratio for Pfizer is 0.8, compared to the industry average of 1.59, indicating a favorable valuation relative to expected earnings growth [6]. Group 6: Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 94, placing it in the top 39% of over 250 industries [7]. - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7].

Company Performance - AbbVie closed at $226.22, down 1.27% from the previous session, underperforming the S&P 500's gain of 0.4% [1] - Over the past month, AbbVie shares increased by 5.95%, outperforming the Medical sector's gain of 1.8% and the S&P 500's gain of 1.02% [1] Upcoming Earnings - AbbVie is set to release its earnings report on October 31, 2025, with an expected EPS of $2.72, reflecting a 9.33% decline year-over-year [2] - The Zacks Consensus Estimate projects net sales of $15.59 billion, which is a 7.81% increase from the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $11.54 per share and revenue at $60.68 billion, indicating increases of 14.03% and 7.72% respectively from the previous year [3] - Recent changes in analyst estimates for AbbVie may indicate shifting business trends, with positive revisions suggesting optimism about the company's outlook [3] Zacks Rank and Stock Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks AbbVie at 3 (Hold) [5] - Over the past month, the Zacks Consensus EPS estimate has decreased by 9.65% [5] Valuation Metrics - AbbVie has a Forward P/E ratio of 19.86, which is higher than the industry average of 14.43 [6] - The company has a PEG ratio of 1.4, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.6 [6] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 97, placing it in the top 40% of over 250 industries [7] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [7]

Core Insights - Johnson & Johnson reported quarterly earnings of $2.8 per share, exceeding the Zacks Consensus Estimate of $2.77 per share, and showing an increase from $2.42 per share a year ago, representing an earnings surprise of +1.08% [1] - The company achieved revenues of $23.99 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.03% and increasing from $22.47 billion year-over-year [2] - Johnson & Johnson's stock has increased approximately 32% since the beginning of the year, outperforming the S&P 500's gain of 13.1% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes in these expectations [4] - The current consensus EPS estimate for the next quarter is $2.56 on revenues of $24.03 billion, and for the current fiscal year, it is $10.86 on revenues of $93.43 billion [7] Industry Context - The Large Cap Pharmaceuticals industry, to which Johnson & Johnson belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Johnson & Johnson (JNJ) has a strong track record of beating earnings estimates, particularly in the last two quarters with an average surprise of 5.96% [1] - The company reported earnings of $2.66 per share for the most recent quarter, falling short of the expected $2.77 per share, resulting in a surprise of 4.14% [2] - For the previous quarter, JNJ exceeded expectations by reporting $2.77 per share against a consensus estimate of $2.57, achieving a surprise of 7.78% [2] Earnings Estimates and Predictions - Recent estimates for Johnson & Johnson have been trending upwards, with a positive Earnings ESP (Expected Surprise Prediction) indicating a potential earnings beat [5] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better has historically led to a positive surprise rate of nearly 70% [6] - Johnson & Johnson currently has an Earnings ESP of +1.53%, suggesting analysts are optimistic about the company's earnings prospects [8] Upcoming Earnings Report - The next earnings report for Johnson & Johnson is expected to be released on October 14, 2025 [8]

Merck (MRK) ended the recent trading session at $87.61, demonstrating a -1.34% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced a drop of 0.2%, and the technology-dominated Nasdaq saw a decrease of 0.67%. The stock of pharmaceutical company has risen by 5.6% in the past month, leading the Medical sector's gain of 2.72% and the S&P 500's gain of 4.06%.Analysts and investors alike will be keeping a ...

Core Viewpoint - Pfizer is well-positioned to continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates significantly in the last two quarters [1]. Earnings Performance - In the most recent quarter, Pfizer reported earnings of $0.78 per share, exceeding the expected $0.58 per share by 34.48% [2]. - For the previous quarter, Pfizer's earnings were $0.92 per share against an estimate of $0.64 per share, resulting in a surprise of 43.75% [2]. Earnings Estimates and Predictions - Estimates for Pfizer have been trending higher due to its history of earnings surprises, with a positive Zacks Earnings ESP of +2.53%, indicating bullish sentiment among analysts regarding its near-term earnings potential [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that stocks with this combination beat estimates nearly 70% of the time [6][8]. Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate than earlier predictions [7]. - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9]. Importance of Earnings ESP - Companies often beat consensus EPS estimates, but this is not the only factor influencing stock price movements. Therefore, checking a company's Earnings ESP before quarterly releases is crucial for investment decisions [10].

Company Performance - Merck (MRK) ended the recent trading session at $78.56, demonstrating a +1.24% change from the preceding day's closing price, outpacing the S&P 500's daily gain of 0.59% [1] - Prior to today's trading, shares of Merck had lost 6.74%, lagging the Medical sector's loss of 0.94% and the S&P 500's gain of 2.72% [1] Earnings Projections - The upcoming earnings report for Merck is projected to show earnings per share (EPS) of $2.37, reflecting a 50.96% increase from the same quarter last year, with revenue expected to be $17.19 billion, showing a 3.18% escalation compared to the year-ago quarter [2] - For the full year, the Zacks Consensus Estimates project earnings of $8.93 per share and revenue of $64.94 billion, representing changes of +16.73% and +1.21%, respectively, from the prior year [3] Analyst Estimates and Valuation - Recent adjustments to analyst estimates for Merck are important as they reflect short-term business trends, with positive revisions indicating analyst optimism about the business and profitability [3] - Merck currently has a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate remaining unchanged over the last 30 days [5] - From a valuation perspective, Merck has a Forward P/E ratio of 8.69, which is a discount relative to the industry average Forward P/E of 13.72, and a PEG ratio of 0.8 compared to the industry average of 1.5 [6] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 85, placing it in the top 35% of all 250+ industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - AbbVie closed at $219.99, reflecting a -1.18% change from the previous day, underperforming the S&P 500's loss of 0.29% [1] - Over the past month, AbbVie shares gained 6.84%, outperforming the Medical sector's loss of 0.33% and the S&P 500's gain of 3.08% [1] Upcoming Earnings - AbbVie's upcoming earnings per share (EPS) are projected to be $3.26, indicating an 8.67% increase from the same quarter last year [2] - Revenue is estimated at $15.54 billion, reflecting a 7.5% rise from the equivalent quarter last year [2] Full Year Projections - For the full year, earnings are projected at $12.02 per share and revenue at $60.64 billion, representing changes of +18.77% and +7.64% from the prior year [3] - Recent adjustments to analyst estimates indicate evolving short-term business trends, with positive revisions suggesting analyst optimism [3] Zacks Rank and Valuation - AbbVie currently holds a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 18.53, which is a premium compared to the industry average of 14.34 [5] - The PEG ratio for AbbVie is 1.33, compared to the Large Cap Pharmaceuticals industry average of 1.53 [6] Industry Overview - The Large Cap Pharmaceuticals industry is part of the Medical sector and holds a Zacks Industry Rank of 106, placing it in the top 43% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - Eli Lilly is expected to report significant earnings growth in the upcoming earnings release, with a projected EPS increase of 444.07% year-over-year and a revenue increase of 40.32% [2]. Company Performance - Eli Lilly's stock closed at $746.98, reflecting a -1.06% change from the previous day, underperforming the S&P 500's loss of 0.55% [1]. - Prior to this trading session, Eli Lilly's shares had gained 8.57%, outperforming the Medical sector's loss of 0.2% and the S&P 500's gain of 3.64% [1]. Earnings Estimates - The upcoming earnings report is anticipated on October 30, 2025, with an expected EPS of $6.42 and quarterly revenue projected at $16.05 billion [2]. - For the annual period, the Zacks Consensus Estimates predict earnings of $23.03 per share and revenue of $61.81 billion, representing increases of +77.29% and +37.22% respectively [3]. Analyst Estimates - Recent modifications to analyst estimates for Eli Lilly indicate a positive outlook, with a 0.21% increase in the Zacks Consensus EPS estimate over the last 30 days [6]. - Eli Lilly currently holds a Zacks Rank of 3 (Hold), reflecting a neutral sentiment among analysts [6]. Valuation Metrics - Eli Lilly is trading at a Forward P/E ratio of 32.78, which is a premium compared to the industry average of 14.65 [7]. - The company has a PEG ratio of 1.06, which is lower than the Large Cap Pharmaceuticals industry's average PEG ratio of 1.53 [7]. Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 63, placing it in the top 26% of over 250 industries [8]. - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [8].

Company Performance - Novartis (NVS) has returned approximately 26.2% since the beginning of the calendar year, outperforming the Medical sector, which has returned an average of -2.6% [4] - The Zacks Consensus Estimate for Novartis' full-year earnings has increased by 1.9% over the past 90 days, indicating improving analyst sentiment and a positive earnings outlook [3] Industry Context - Novartis is part of the Large Cap Pharmaceuticals industry, which consists of 10 companies and currently ranks 52 in the Zacks Industry Rank. The average performance of stocks in this group is 0% year-to-date, highlighting Novartis' superior performance [5] - In comparison, Arbutus Biopharma, another outperforming stock in the Medical sector, has seen a year-to-date increase of 34.6% and is part of the Medical - Biomedical and Genetics industry, which has a ranking of 97 and has moved up by 3.1% since the start of the year [4][6]